Trial Profile
A Multicenter, Randomized, Double Blind, Crossover Study Comparing the Effect of MK0524 With Placebo and Concomitant Administration of MK0524 Plus Montelukast in Adult Patients With Chronic Asthma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Laropiprant (Primary) ; Montelukast
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Merck & Co; Merck Sharp & Dohme
- 16 Nov 2008 New trial record.